Catalog No.S8812

For research use only.

CM-272 is a novel first-in-class dual reversible inhibitor of G9a (GLP) and DNMTs with IC50 of 8 nM, 382 nM, 85 nM, 1200 nM, 2 nM for G9a, DNMT1, DNMT3A, DNMT3B, GLP, respectively. CM-272 prolongs survival in in vivo models of haematological malignancies by at least in part inducing immunogenic cell death.

CM272 Chemical Structure

CAS No. 1846570-31-7

Selleck's CM272 has been cited by 1 Publication

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description CM-272 is a novel first-in-class dual reversible inhibitor of G9a (GLP) and DNMTs with IC50 of 8 nM, 382 nM, 85 nM, 1200 nM, 2 nM for G9a, DNMT1, DNMT3A, DNMT3B, GLP, respectively. CM-272 prolongs survival in in vivo models of haematological malignancies by at least in part inducing immunogenic cell death.
G9a [1]
(Cell-free assay)
DNMT3A [1]
(Cell-free assay)
DNMT1 [1]
(Cell-free assay)
DNMT3B [1]
(Cell-free assay)
8 nM 85 nM 382 nM 1200 nM
In vitro

The GI50 for CM-272 after 48 h of treatment in ALL, AML and DLBCL-derived cell lines is in the nM range and is associated with a decrease in global levels of H3K9me2 and 5mC. CM-272 inhibits cell proliferation, blocks cell cycle progression and induces apoptosis in ALL, AML and DLBCL cell lines in a dose-dependent manner. CM-272 induces IFN response and immunogenic cell death.[1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CEMO1 MWLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NUPwS|JYPDhiaILz MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOHTV:xJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGOgZZN{[XluIFfJOVA:OC5{MUlOwG0v M3\BZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OEmwPFMxLz5{OUi5NFg{ODxxYU6=
CEMO1 NIf0PYpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEPuenM1QCCqcoO= MXXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDDSW1QOSClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRUKGG|c3H5MEBIUTVyPUCuNlE5|ryPLh?= MoTOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7NUO4NFkoRjJ7OUWzPFA6RC:jPh?=
MV4-11 M4qzcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH;Pepg1QCCqcoO= M{fWO2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1XPC1zMTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSVIHHzd4F6NCCJSUWwQVAvOjZ7zszNMi=> MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTl3M{iwPUc,Ojl7NUO4NFk9N2F-
OCI-LY3 NUjSc5dwSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NV3yWpRuPDhiaILz NEXKSYRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF;DTU1NYTNiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VWyCjc4PhfUwhT0l3ME2wMlQxQc7:TT6= M1;6WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OEmwPFMxLz5{OUi5NFg{ODxxYU6=
OCI-LY3 MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn\MOFghcHK| M1HMeGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG9EUS2OWUOgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WUzDhd5NigSxiR1m1NF0xNjRyOd88UU4> NIOycXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUm1N|gxQSd-Mkm5OVM5ODl:L3G+
OCI-LY10 M2PmOmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MYS0PEBpenN? M1zwb2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iT1PJMWx[OTBiY3XscJMh[W[2ZYKgOFghcHK|IHL5JG1VWyCjc4PhfUwhT0l3ME2wMlQ2Pc7:TT6= NFzFcGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi5NFg{OCd-Mkm4PVA5OzB:L3G+
OCI-LY10 MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mo\pOFghcHK| MofQS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gU2NKNUy\MUCgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WUzDhd5NigSxiR1m1NF0xNjR3Nd88UU4> MnTkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7NUO4NFkoRjJ7OUWzPFA6RC:jPh?=
LAL-CUN-2 MnPKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWe1ZXp7PDhiaILz NW\MeolzT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVEGOLVPVUk0zKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHMh[XO|YYmsJGdKPTB;MD62OlTPxE1w NIrqflM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUm1N|gxQSd-Mkm5OVM5ODl:L3G+
THLE2 MVHDfZRwfG:6aXPpeJkh[XO|YYm= Ml2wO|IhcHK| MXnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDUTGxGOiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiTFO1NF0yNjd6zszNMi=> NXXVNWl5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4PVA5OzBpPkK5PFkxQDNyPD;hQi=>
THLE2 MnTuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2jVUlczKGi{cx?= NUO3clk6T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hXEiORUKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiTFO1NF0yNjd6zszNMi=> NXizXZRDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm5OVM5ODlpPkK5PVU{QDB7PD;hQi=>
In vivo

CM272 therapy induces a statistically significant increase in overall survival (OS) in mice in comparison with control animals. Global H3K9me2 and 5mC levels are reduced in leukaemic cells obtained from mice engrafted with ALL-derived CEMO-1 cells after 1 week of treatment and no significant weight loss is observed in treated animals. CM272 shows dose-dependent efficacy and a dose of 2.5 mg/kg of CM272 is adequate to demonstrate the positive anti-tumour efficacy in mice engrafted with ALL-derived CEMO-1 cells.[1].

Protocol (from reference)

Cell Research:


  • Cell lines: ALL, AML, DLBCL, CEMO-1, LAL-CUN-2, MV4-11, OCI-AML-2, OCI-Ly3, OCI-Ly10 cell lines
  • Concentrations: --
  • Incubation Time: 24, 48, 72 and 96h
  • Method:

    "100.000 cells of CEMO-1, LAL-CUN-2, MV4-11 and OCI-AML-2 cell lines are cultured at a density of 1x106 cells/mL and treated for 12, 24, 48 and 72 hours with CM-272 at different concentrations (GI25, GI50 and GI75). In the case of OCI-Ly3 and OCI-Ly10, cells are treated with 100, 400 and 1000 nM for 24, 48, 72 and 96h. Cells are washed twice with phosphatebuffered saline (PBS) and resuspended in 1X Binding Buffer at a concentration of 1x106 cells/mL. 1 µL of FITC Annexin V antibody and 2 µL of propidium iodide are added and incubated for 15 min at RT in the dark. Finally, 400 µL of 1X Binding Buffer are added to each tube and analyzed by flow cytometry within 1 h. "

Animal Research:


  • Animal Models: 6–8-week-old female BALB/cA−Rag2 γc mice
  • Dosages: 1, 2.5 mg/kg
  • Administration: IV

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 478.63



CAS No. 1846570-31-7
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy CM272 | CM272 supplier | purchase CM272 | CM272 cost | CM272 manufacturer | order CM272 | CM272 distributor